updat model iqvia follow earn releas tuesday morn juli
quarter result arguabl impress sinc merger
im quintil stronger revenu key segment higher
margin impress new contract win increas guidanc also view result
encourag start earn season broader pharma outsourc
servic group larg small biopharma compani seek drive improv
effici across manufactur sale market
iqv second-quart result expect top bottom line
million cent respect book expectationsund
quarterli book-to-bil ratio time versu estim
net award roughli year-ago level manag commentari
organ growth approxim technolog
 analyt solut formerli commerci solut busi also reassur
exceed estim illustr exhibit iqv consolid organ
revenu growth highest past five quarter gradual upward trend
bolster confid compani longer lose share
increas revenu estim million billion
total organ constant currenc increas ep estim
cent expect underli organ growth technolog
analyt solut segment remain around segment
hold steadi solid book past year allow organ growth
pick beyond model consolid organ growth acceler
percentag point next two year unchang prior
model expect manag on-going focu cost cut aggress
capit deploymentvia activ share repurchasesshould sustain bottom-
line growth midteen next year maintain outperform rate
view current valuat attract
iqvia integr inform technology-en healthcar servic provid annual revenu base
approach billion form merger quintil im health compani employ
roughli employe oper countri compani world lead provid
pharmaceut sale prescript data leader outsourc drug develop commerci
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
return equiti ttm
exhibit iqvia consolid organ growth present
technolog analyt solut increas organ constant-curr basi quarter compar
target total revenu segment beat model million driven mainli sever smaller acquisit
ad percentag point growth remaind year expect roughli organ growth
acquisit benefit declin second half year aggreg estim as-report growth
segment previous
 increas organ constant-curr basi quarter well target
remaind year expect organ growth hold steadi around level compani book-to-bil ratio
quarter ratio year-over-year backlog growth methodolog
quarter give us addit comfort organ growth busi gradual improv model
organ growth segment compar previous next-gen offer
appear gain momentum demand environ seemingli continu strong next data
point cro demand come icon iclr outperform report thursday morn
contract sale medic solut decreas constant-curr basi quarter largest
declin sinc merger compar estim declin expect double-digit rate declin
continu rest year unchang model midsingle-digit declin next year
previous model declin
increas revenu estim million billion ep estim
estim organ growth full year compar previous
increas revenu estim million billion ep estim
estim organ growth compar previous result lower expect
contract medic solut formerli segment
valuat stock thought
follow tuesday increas trade time updat estim valuat
turn discount cro group time maintain outperform rate time given continu
solid book trend path improv organ growth beyond updat model iqvia follow
xxsourc compani report william blair william blair
exhibit updat iqvia hold incom statement summari
profit gener administr expens amort incom includ option beg incom expens tax investe non-controlling interests/minor hedg incom tax non control item net incom excl non-recurring item incl option beg averag share outstand averag share outstand analysi gross rate revenu begin excl foreign exchang effect pro forma beg organ pro forma beg incom excl non-recur excl non-recur item incl blair compani estimatesourc compani report william blair compani llc estim import disclosur
